Current Report Filing (8-k)
February 07 2017 - 8:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): February 7, 2017
VBI
VACCINES INC.
(Exact
name of registrant as specified in its charter)
British
Columbia, Canada
(State
or other jurisdiction
of
incorporation)
|
|
000-37769
(Commission
File
Number)
|
|
N/A
(IRS
Employer
Identification
No.)
|
222
Third Street, Suite 2241
Cambridge,
Massachusetts
(Address
of principal executive offices)
|
|
|
|
02142
(Zip
Code)
|
(617)
830-3031
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
7.01 Regulation FD Disclosure.
On
February 7, 2017, VBI Vaccines Inc. issued a press release. A copy of the press release is furnished herewith as Exhibit 99.1
and incorporated by reference in this Item 7.01.
The
information disclosed under this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities
and Exchange Commission nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except
as expressly set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
No.
|
|
Description
|
99.1
|
|
Press
Release dated February 7, 2017*
|
*Furnished
herewith
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VBI
Vaccines Inc.
|
|
|
|
Date:
February 7, 2017
|
By:
|
/s/
Jeff Baxter
|
|
|
Jeff
Baxter
|
|
|
President
and Chief Executive Officer
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
99.1
|
|
Press
Release dated February 7, 2017*
|
*Furnished
herewith
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2024 to May 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From May 2023 to May 2024